KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Change in Accured Expenses (2016 - 2025)

Cvs Health (CVS) has disclosed Change in Accured Expenses for 16 consecutive years, with -$855.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 78.5% year-over-year to -$855.0 million, compared with a TTM value of $2.0 billion through Dec 2025, up 156.83%, and an annual FY2025 reading of $2.0 billion, up 156.83% over the prior year.
  • Change in Accured Expenses was -$855.0 million for Q4 2025 at Cvs Health, down from $1.1 billion in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.5 billion in Q3 2022 and bottomed at -$2.4 billion in Q2 2024.
  • Average Change in Accured Expenses over 5 years is $466.3 million, with a median of $148.5 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses soared 9580.0% in 2021, then plummeted 632.89% in 2024.
  • Year by year, Change in Accured Expenses stood at $968.0 million in 2021, then plummeted by 193.8% to -$908.0 million in 2022, then surged by 44.16% to -$507.0 million in 2023, then rose by 5.52% to -$479.0 million in 2024, then crashed by 78.5% to -$855.0 million in 2025.
  • Business Quant data shows Change in Accured Expenses for CVS at -$855.0 million in Q4 2025, $1.1 billion in Q3 2025, and -$118.0 million in Q2 2025.